C4 Therapeutics, Inc. (CCCC)
| Market Cap | 393.95M +73.7% |
| Revenue (ttm) | 32.28M +7.2% |
| Net Income | -91.09M |
| EPS | -0.71 |
| Shares Out | 131.32M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,453,874 |
| Open | 3.110 |
| Previous Close | 3.150 |
| Day's Range | 2.930 - 3.160 |
| 52-Week Range | 1.690 - 5.170 |
| Beta | 3.16 |
| Analysts | Strong Buy |
| Price Target | 12.50 (+316.67%) |
| Earnings Date | Nov 5, 2026 |
About CCCC
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutat... [Read more]
Financial Performance
In 2025, C4 Therapeutics's revenue was $35.95 million, an increase of 1.02% compared to the previous year's $35.58 million. Losses were -$104.99 million, -0.31% less than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for CCCC stock is "Strong Buy." The 12-month stock price target is $12.5, which is an increase of 316.67% from the latest price.
News
C4 Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
Cemsidomide showed a 53% ORR at its 100 mcg RP2D in a 72-patient first-in-human study, with a differentiated safety profile claimed by management. MOMENTUM enrollment is guided to finish in Q1 2027, with initial investigator-assessed data expected in H2 2027.
C4 Therapeutics price target lowered to $6 from $7 at Guggenheim
Guggenheim lowered the firm’s price target on C4 Therapeutics (CCCC) to $6 from $7 and keeps a Buy rating on the shares.
C4 Therapeutics reports Q3 EPS (16c), consensus (21c)
Reports Q3 revenue $8.47M, consensus $8.52M. “Throughout the year, we have continued to build evidence supporting cemsidomide’s potential as a backbone therapy across the multiple myeloma treatment la...
C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Cemsidomide Phase 2 MOMENTUM Trial On Track to Complete Enrollment in 1Q 2027 with Initial ORR Data Expected in 2H 2027 Enrollment Complete for First Safety Cohort in Phase 1b Trial of Cemsidomide wit...
C4 Therapeutics Quarterly report: Q3 2026
C4 Therapeutics has published its Q3 2026 quarterly earnings report on November 5, 2026.
C4 Therapeutics Earnings release: Q3 2026
C4 Therapeutics released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
C4 Therapeutics to Participate in Upcoming November Investor Conferences
WATERTOWN, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) sci...
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, ...
C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders
WATERTOWN, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) sci...
C4 Therapeutics initiated with a Buy at Lake Street
Lake Street initiated coverage of C4 Therapeutics (CCCC) with a Buy rating and $11 price target Management describes cemsidomide as the most potent and selective IKZF1/3 degrader in its class…
Insmed Appoints Two New Directors to Its Board
—Paul Hudson, Former CEO of Sanofi and Novartis Pharmaceuticals, and Utpal Koppikar, CFO of Verily Health and Veteran Biopharma Finance Leader, Join as New Independent Directors— BRIDGEWATER, N.J., Oc...
C4 Therapeutics initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of C4 Therapeutics (CCCC) with an Overweight rating and $10 price target The firm cites the potential of the company’s lead asset cemsidomide in multiple myeloma for…
C4 Therapeutics Slides: Corporate presentation
C4 Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 25, 2026.
C4 Therapeutics presents biomarker data from Phase 1 trial of cemsidomide
C4 Therapeutics (CCCC) presented new biomarker data from its Phase 1 clinical trial of cemsidomide in combination with dexamethasone in patients with relapsed/refractory multiple myeloma, RRMM, in a p...
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide's Dual Mechanism of Action
C4 Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
Cemsidomide is advancing in multiple myeloma with strong efficacy, tolerability, and ongoing pivotal trials, including combination studies with T-cell engagers. The late-line market is expected to grow, and the platform is expanding into new disease areas, supported by collaborations and a runway through 2028.
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting
WATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) sc...
C4 Therapeutics reports Q2 EPS (18c), consensus (23c)
Reports Q2 revenue $6.64M, consensus $4M. “The first half of 2026 was a period of execution for cemsidomide, our next-generation IKZF1/3 degrader, and our clinical development plan. At the EHA…
C4 Therapeutics Earnings release: Q2 2026
C4 Therapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
C4 Therapeutics Quarterly report: Q2 2026
C4 Therapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.
C4 Therapeutics Slides: Corporate presentation
C4 Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 10, 2026.
C4 Therapeutics Transcript: AGM 2026
The meeting confirmed a quorum and addressed four proposals, including director elections, executive compensation, auditor ratification, and a stock plan amendment. All proposals passed by majority vote, and no shareholder questions were raised.
C4 Therapeutics Transcript: KOL event
The event highlighted the evolving multiple myeloma landscape and the foundational role of IKZF1/3 degraders, with cemsidomide showing strong efficacy and safety in heavily pre-treated patients. Strategic development includes late-line and combination trials, aiming to establish cemsidomide as a backbone therapy.
C4 Therapeutics Slides: KOL event
C4 Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 18, 2026.
C4 Therapeutics presents further analysis from cemsidomide trial
C4 Therapeutics (CCCC) will present further analysis from its fully enrolled Phase 1 trial of cemsidomide, a next-generation oral IKZF1/3 degrader, in combination with dexamethasone for the treatment ...